Published in Malaria Weekly, September 9th, 1996
AMA-1, an asexual blood-stage antigen of Plasmodium falciparum, is a candidate for testing as a malaria vaccine component, noted Pauline E. Crewther, the Walter and Eliza Hall Institute of Medical Research, Victoria, Australia, and colleagues.
Crewther et al. investigated the impact of diversity in AMA-1 on the efficacy realized by immunization with recombinant AMA-1 ("Protective Immune Responses to Apical Membrane Antigen 1 of Plasmodium chabaudi Involve Recognition of Strain-Specific Epitopes," Infection and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Malaria Weekly